FRE.DE

$46.44

Market ClosedAs of Mar 17, 4:37 PM UTC

Fresenius SE & Co.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$46.44
Potential Downside
15.3%
Whystock Fair Value$39.32
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Care Facilities

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$26.16B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
22.65
Beta
Defensive asset. Lower volatility than the S&P 500.
0.91
Div Yield
Strong income play. Yield provides a meaningful total return floor.
224.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
5.89%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.68

Recent News

Insider Monkey
Mar 13, 2026

Fresenius Medical Care AG (FMS) Looks to Improve Profitability After Smashing Q4 Expectations

Fresenius Medical Care AG (NYSE:FMS) is among the best German stocks to buy according to analysts. On February 24, Fresenius Medical Care AG (NYSE:FMS) released its Q4 2025 results. The company posted EPS of €1.14, compared to €0.23 in the same quarter in 2024. It delivered revenue of €5.1 billion, flat from the year-ago quarter. […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 5, 2026

Here's Why Fresenius (FMS) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Bloomberg
Mar 3, 2026

Health Industry Must Navigate a New World Order: Fresenius CEO

Fresenius CEO Michael Sen says the health industry must analyze and navigate "a new world order" in which exchanges have become transactional and national interests the priority. Sen discussed the impact of geopolitical uncertainty on the German company's operations in an interview with Francine Lacqua on Bloomberg's "The Pulse".

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Mar 1, 2026

Assessing Fresenius SE KGaA (XTRA:FRE) Valuation After Recent Earnings And Shareholder Returns

Why Fresenius SE KGaA (XTRA:FRE) is Back on Investors’ Radars Fresenius SE KGaA (XTRA:FRE) has attracted fresh attention after posting annual revenue of €22.4b and net income of €1.1b, prompting investors to reassess how the healthcare group’s valuation compares with its recent performance. See our latest analysis for Fresenius SE KGaA. The 1 day share price return of a 0.8% decline and 7 day share price return of a 2.2% decline sit against a 30 day share price return of 9.1% and a 1 year...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Feb 27, 2026

Pacira BioSciences, Inc. Q4 2025 Earnings Call Summary

Moby summary of Pacira BioSciences, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.